Abnormal activation of SETBP1 through overexpression or missense mutations is highly recurrent in various myeloid malignancies; however, it is unclear whether such activation alone is able to induce leukemia development. Here we show that Setbp1 overexpression in mouse bone marrow progenitors through retroviral transduction is capable of initiating leukemia development in irradiated recipient mice. Before leukemic transformation, Setbp1 overexpression significantly enhances the self-renewal of hematopoietic stem cells (HSCs) and expands granulocyte macrophage progenitors (GMPs). Interestingly, Setbp1 overexpression also causes transcriptional repression of critical hematopoiesis regulator gene Runx1 and this effect is crucial for Setbp1-induced transformation. Runx1 repression is induced by Setbp1-mediated recruitment of a nucleosome remodeling deacetylase (NuRD) complex to Runx1 promoters and can be reversed by treatment with histone deacetylase (HDAC) inhibitors Entinostat and Vorinostat. Moreover, treatment with these inhibitors caused efficient differentiation of Setbp1 activation-induced leukemia cells in vitro, and significantly extended the survival of mice transplanted with such leukemias, suggesting that HDAC inhibition could be an effective strategy for treating myeloid malignancies with SETBP1 activation.
INTRODUCTION
SETBP1 is a large nuclear protein first identified through its interaction with oncoprotein SET. 1 Growing evidence suggests that its abnormal activation may have an important role in the development of multiple myeloid malignancies. Overexpression of SETBP1 was previously found in over 27% acute myeloid leukemia (AML) patients of old age, 2 suggesting its common involvement in AML development. Increased SETBP1 expression was also later detected in a subset of CML blast crisis patients. More recently, we and others have found highly recurrent missense mutations of SETBP1 in patients of atypical chronic myeloid leukemia, 3 chronic myelomonocytic leukemia, 4 secondary AML, 4 chronic neutrophilic leukemia 5, 6 and juvenile myelomonocytic leukemia, 7 which stabilize SETBP1 protein through decreasing its degradation. 3 Multiple mechanisms could contribute to the involvement of SETBP1 in leukemia development. SETBP1 may promote inhibition of PP2A through physical interaction with SET.
2 Setbp1 can also function as an AT-hook transcription factor to activate the transcription of oncogene Hoxa9 and Hoxa10. 8 We have also shown that overexpression of Setbp1 can promote the selfrenewal of myeloid progenitors in vitro and in vivo, further suggesting that Setbp1 could have a direct role in conferring unlimited self-renewal capability to leukemia-initiating cells in myeloid leukemias. 8, 9 However, it remains unclear whether SETBP1 is a potent oncogene capable of inducing leukemia development and whether additional mechanism(s) may be important for its leukemia-promoting effects. It is also critical to identify targeted therapies for leukemias with SETBP1 activation because of their association with poor prognosis. 2, 4 Chromatin remodeling is a critical step for proper control of gene transcription and is dynamically regulated by recruitment of chromatin-associated proteins that can be categorized into epigenetic 'writers', 'erasers' and 'readers'. 10 Different chemical marks can be added to DNA or histones by 'writers' such as DNA and histone methyltransferases, removed by 'erasers' including histone deacetylases (HDACs) and demethylases, and bound to by 'readers' to directly regulate transcription. Abnormal epigenetic regulation has an important role in leukemia development, as many of these writers, erasers and readers have been found mutated in leukemias such as MLL and EZH2 or gets recruited by leukemic fusion proteins including AML1/ETO and PML/RAR. [11] [12] [13] [14] [15] The presence of three AT-hook DNA-binding motifs in Setbp1 suggests that it may be involved in epigenetic regulation, as proteins with such motifs are known to be important components of large chromatin-remodeling complexes. [16] [17] [18] However, this possibility has not been examined.
Here we showed that overexpression of Setbp1 in 5-fluorouracil (5-FU)-treated bone marrow (BM) progenitor cells is capable of inducing myeloid leukemia development in recipient mice. Before leukemia development, increased expression of Setbp1 dramatically enhanced self-renewal of hematopoietic stem cells (HSCs) and promoted the expansion of granulocyte macrophage progenitors (GMPs). We also identified a novel function of Setbp1 as a transcriptional repressor through the recruitment of the Nucleosome Remodeling Deacetylase (NuRD) complex. Through this mechanism, Setbp1 directly represses the transcription of tumor suppressor gene Runx1, which is critical for Setbp1-induced transformation. Our results further showed that treatment with class I HDAC inhibitors can relieve Runx1 repression by Setbp1 and represents a promising strategy for treating human myeloid leukemias with SETBP1 activation.
MATERIALS AND METHODS Mice
C57BL/6 and B6-Ly5.2 female mice (7-12 weeks old; Charles River, Frederick, MD, USA) were maintained in the animal facility of Center for Laboratory of Animal Medicine at Uniformed Services University of the Health Sciences (USUHS, Bethesda, MD, USA). All mouse experiments were carried out according to protocols approved by the USUHS Institutional Animal Care and Use Committee.
Retrovirus generation
The pMYs-Setbp1-IRES-GFP retroviral construct was described previously. 8 The murine Runx1 cDNA from pcDNA3.1-Flag-Runx1FL 19 (Addgene plasmid 14585) was cloned into MSCV-neo using EcoRI and XhoI sites to generate MSCV-Runx1-neo. High titer retroviruses were produced by transient transfection of Plat-E cells using Fugene-6 (Roche, Indianapolis, IN, USA). Viral titer was assessed by serial dilution and infection of NIH-3T3 cells.
Retroviral transduction and BM transplantation
5-FU-treated BM cells from C57BL/6 mice were extracted and expanded in culture as described. 20 These expanded BM cells were subsequently infected three times with high-titer retrovirus-carrying Setbp1 cDNA (pMYsSetbp1-IRES-GFP) or GFP only (pMYs-IRES-GFP) on retronectin-coated plates. For transplantation, 0. + ) population in the BM was analyzed at 3 months after transplantation using 5-FU-treated cells. lin − cells were obtained as mentioned above and subsequently stained with anti-Sca-1-APC, anti-CD34-Alexa fluor-700, anti-c-Kit-PE and anti-FcR-II/III-PE-Cy7 and were analyzed using BD LSRII flow cytometer (BD Biosciences).
Chromatin immunoprecipitation
Mouse myeloid progenitors immortalized by FLAG-tagged Setbp1 were generated as described. 8 Chromatin immunoprecipitation (ChIP) analyses were performed using the ChIP-IT Express kit (Active Motif, Carlsbad, CA, USA). Immunoprecipitations were performed using FLAG M2 (SigmaAldrich, St Louis, MO, USA), mouse monoclonal anti-HDAC1 antibody (10E2, #5356, Cell Signaling Technologies, Danvers, MA, USA), 21 rabbit polyclonal anti-acetylated histone H3 (#39139, Active Motif), 22 rabbit polyclonal antiMta2 (sc-28731, Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal anti-Mbd3 (A302-528A, Bethyl Laboratories, Montgomery, TX, USA), mouse IgG (G3A1, #5415, Cell Signaling Technologies), rabbit polyclonal anti-Chd4 (14173-1, Proteintech, Chicago, IL, USA) and rabbit IgG (#P120-101, Bethyl Laboratories). Chromatin DNA was purified using the MinElute PCR Purification Kit (QIAGEN, Hilden, Germany) and quantified using real-time PCR. See Supplementary Information for Runx1 promoter-specific primer sequences. Figure 2) . To examine the clonality of the leukemias, we carried out Southern blot analysis on genomic DNA from the leukemic spleens using a GFP-specific probe. Integration bands of similar intensity were observed in the majority of the leukemias, suggesting that they are mostly monoclonal (Supplementary Figure 3) . Cell lines can be efficiently established from these leukemias by culturing leukemia cells in the presence of SCF and IL-3. Knockdown of Setbp1 or its known critical targets Hoxa9 and Hoxa10 in these leukemia cell lines dramatically reduced their colony formation on methylcellulose ( Supplementary Figures 4 and 5 ), suggesting that their expressions are critical for the maintenance of leukemia cells. Collectively, these results suggest that SETBP1 is a potent oncogene capable of inducing myeloid leukemia development. Figure  6 ). Furthermore, an average of over 80-fold higher engraftment potential was detected for Setbp1-transduced cells over control cells in secondary recipients receiving 500 GFP + LSK cells purified from the primary recipients at 16 weeks after transplantation (Figure 2e ). These results support the notion that increased expression of Setbp1 significantly enhances the self-renewal capability of HSCs.
RESULTS

Overexpression of
Setbp1 represses Runx1 transcription through recruitment of Hdac1 As both activation of proto-oncogenes and suppression of tumor suppressors are likely required for cancer transformation, we were interested to learn whether Setbp1 may additionally induce repression of tumor suppressor gene(s) besides activating oncogenes Hoxa9 and Hoxa10 during leukemia induction. Human AMLs with high SETBP1 expression display significantly lower mRNA levels of tumor suppressor gene RUNX1 compared with AMLs with low SETBP1 expression (Supplementary Figure 7) . Similar to Setbp1 overexpression, Runx1 loss has also been shown to induce expansion of HSCs and GMPs. These lines of evidence suggest that SETBP1 may suppress RUNX1 expression. In supporting this notion, Runx1 mRNA levels were significantly reduced in primary myeloid progenitors from C57BL/6 mice at 48 h after infection with Setbp1 virus (Figure 3a) . Meanwhile, knockdown of Setbp1 using a GFP-specific lentiviral short hairpin RNA in Setbp1-immortalized S3 cells 8 induced substantial increases in Runx1 Setbp1 represses Runx1 transcriptionmRNA and protein levels (Figure 3b ). The repression of Runx1 by Setbp1 is also critical for Setbp1-induced immortalization and transformation, as ectopic Runx1 expression in S3 cells and Setbp1-induced leukemia cell line BL12 dramatically inhibits their colonyforming capability (Supplementary Figure 8) .
The rapid downregulation of Runx1 mRNA levels by Setbp1 overexpression suggests that Runx1 may be a direct transcriptional target of Setbp1. To test this idea, we carried out chromatin immunoprecipitation (ChIP) assays in mouse myeloid progenitors immortalized by FLAG-tagged Setbp1 (Figure 3c ). In two × 10 2 cells/mouse) of LSK cells transduced with pMYs-Setbp1-IRES-GFP (black bars) or pMYs-IRES-GFP (white bars) virus (primary transplantation, n = 5 per group at 4 and 8 weeks and n = 1 per group at 16 weeks; secondary transplantation, n = 4 and n = 3 for pMYsSetbp1-IRES-GFP and pMYs-IRES-GFP groups, respectively, at all indicated time points. Data are presented as means ± s.d., **P o0.01 (two-tailed Student's t-test).
independently immortalized myeloid progenitor populations, genomic regions within the two alternative promoters of Runx1 were significantly enriched in immunoprecipitates prepared using FLAG M2 antibody over control IgG immunoprecipitates (Figure 3c ), indicating that Setbp1 may directly repress Runx1 transcription in myeloid progenitors. 23 Proteins containing AT-hook motifs are known to participate in chromatin remodeling. [16] [17] [18] To investigate whether epigenetic regulation is involved in this transcriptional repression of Runx1 induced by Setbp1, we examined changes in histone modifications at Runx1 promoters after Setbp1 knockdown in the same cells. We detected significant increases in histone H3 acetylation levels at Runx1 promoters after Setbp1 knockdown, whereas no significant changes in total acetylated histone H3 levels were observed (Figure 4a ), suggesting that Setbp1 may repress Runx1 transcription by inducing histone H3 deacetylation at its promoters. In support of this concept, significant bindings of Hdac1 in a similar pattern as Setbp1 bindings could be detected at Runx1 promoters
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Relative expression by ChIP analysis (Figure 4b ). Moreover, Hdac1 knockdowns significantly increased Runx1 mRNA levels in these cells, which were also accompanied by significant reductions in their colony-forming capability (Supplementary Figure 9) . In addition, Hdac1 bindings at Runx1 promoters were dramatically reduced by Setbp1 knockdown, whereas total Hdac1 protein levels were not affected (Figure 4b ), indicating that Setbp1 may be responsible for recruiting Hdac1 to Runx1 promoters. Collectively, these results suggest that Setbp1 may repress Runx1 transcription through recruiting Hdac1, which induces histone deacetylation at its promoters.
Runx1
The NuRD complex is recruited to Runx1 promoters HDAC1 has been frequently identified in distinct multiprotein complexes including the Sin3, NuRD and CoREST complexes. 24 Particularly, the NuRD complex was shown previously to repress gene transcription in myeloid progenitors. 15 Therefore, we first tested the possibility that Hdac1 may be recruited to Runx1 promoters as part of the NuRD complex. By ChIP analysis, significant bindings of Chd4, Mbd3 and Mta2, representing the unique components of the NuRD complex, were all detected at both Runx1 promoters in Setbp1-immortalized myeloid progenitors (Figure 5a ), suggesting that Setbp1-induced Runx1 repression is mediated by the NuRD complex. Consistent with this idea, knockdown of Mbd3 or Mta2 significantly increased Runx1 mRNA levels in Setbp1-induced leukemia cells (Supplementary Figures 10  and 11 ). To further test the possibility that Setbp1 may physically associate with the NuRD complex, we transiently expressed 3xFLAG-tagged Setbp1 in 293T cells and examine the association of endogenous NuRD complex components with Setbp1 by immunoprecipitation using FLAG M2 antibody. NuRD complex components including MBD3, HDAC1, MTA2 and CHD4 could be readily detected in FLAG M2 immunoprecipitates prepared from transfected cells but not in that of non-transfected cells or precipitates prepared using control IgG (Figure 5b ). Setbp1 along with HDAC1 and CHD4 can also be significantly precipitated from the transfected cells using a MTA2-specific antibody (Figure 5c ). These results suggest that Setbp1 may directly recruit the NuRD complex to Runx1 promoters through physical interaction.
HDAC inhibitors are effective in treating myeloid leukemias with Setbp1 activation HDAC inhibitors have been shown to exert inhibitory effects against myeloid leukemias induced by AML/ETO, PLZF/RARa or Hoxa9/Meis1. [25] [26] [27] Given that Runx1 repression by Setbp1-mediated Hdac1 recruitment is required for efficient colony formation by Setbp1-induced leukemia cells, we explored the therapeutic potential of HDAC inhibitors for treating leukemias induced by Setbp1 overexpression. As expected, Runx1 mRNA and protein levels were significantly upregulated in Setbp1-induced BL3 and BL12 leukemia cell lines by treatment with HDAC inhibitors Entinostat and Vorinostat (Supplementary Figure 12) . Treatment with these inhibitors also completely ablated colony formation by these leukemia cells and Setbp1-immortalized S3 cells (Figure 6a ). Cytospin analysis of treated cells in liquid culture further suggests the induction of myeloid differentiation (Figure 6b ), which was confirmed by significantly increased expression of differentiation markers including Cd11b, Lyz2 and Csf1r (Supplementary Figure 13) . As SETBP1 missense mutations were thought to cause SETBP1 activation by increasing its protein stability 3 and were also found to associate with high SETBP1 mRNA levels, 4 we additionally tested effects of HDAC inhibitors on mouse myeloid progenitors immortalized by ectopic expression of mutant Setbp1 carrying such a mutation in leukemia patients. As expected, both HDAC inhibitors also induced identical effects in these cells to cells immortalized by wild-type Setbp1 (Supplementary Figure 14) . To further test the potential efficacy of HDAC inhibition in treating leukemias with SETBP1 overexpression in vivo, we transplanted mice with two independent primary mouse myeloid leukemias induced by Setbp1 overexpression, and treated the recipient mice with Entinostat or vehicle once every 3 days for 21 days starting from 7 days post transplantation (Figure 6c ). All recipient mice treated with vehicle become moribund because of leukemia development after 2 weeks. In contrast, Entinostat treatments significantly prolonged the survival of all leukemic mice with up to 90% extension of their survival time. Collectively, these results suggest that HDAC inhibition may represent a promising therapeutic strategy for treating myeloid leukemias with SETBP1 activation.
DISCUSSION
Several lines of evidence suggested the involvement of SETBP1 in myeloid leukemia development including its frequent activation by overexpression or mutations in various myeloid malignancies, [2] [3] [4] 7 capabilities to promote PP2A inhibition and self-renewal of myeloid progenitors by upregulating Hoxa9 and Hoxa10, 2, 8 and cooperation with BCR/ABL 8 and ASXL1 mutations 28 in leukemia development; however, it was unclear whether its activation is critical for the initiation or progression of myeloid leukemia. Here we show that SETBP1 overexpression can be a 'driver' mutation in the initiation of AML development as over half of mice receiving mouse BM progenitors transduced by a Setbp1-expressing retrovirus developed myeloid leukemia within 10 months. Most of these leukemias also express physiologically relevant levels of Setbp1 as similarly increased levels of SETBP1 mRNA were observed in human myeloid leukemias with overexpression of wild-type SETBP1 or SETBP1 missense mutations when compared with normal BM controls. 2, 4 The relatively long disease latency and over 50% disease penetration in our model further suggest that Setbp1 overexpression by itself is not sufficient to cause full transformation, which likely requires additional mutations. As Hoxa9 is a critical target of Setbp1 and is known to cooperate with Meis1 in leukemia induction, it is possible that one such cooperating mutation for Setbp1 is activation of Meis1. However, Meis1 overexpression was only Animals were injected intraperitoneally every 3 days starting from 7 days after transplantation until 21 days after transplantation. *P o0.05; **P o0.01 (log-rank test).
detected in one out of six Setbp1-induced leukemias (data not shown), suggesting that other unknown cooperating mutations/ pathways likely exist for Setbp1. Identification of these mutations/ pathways, which may be achieved by cloning the virus insertion sites from these leukemias, 20 should help advance our understanding of the molecular mechanisms underlying SETBP1-induced leukemia development.
Our study identifies Runx1 as a critical transcriptional repression target of Setbp1 in promoting myeloid leukemia development. Similar to Hoxa9 and Hoxa10 knockdowns, increased Runx1 expression dramatically inhibited colony formation of Setbp1-induced leukemia cells. The repression of Runx1 by Setbp1 is also supported by the similar effects on normal adult hematopoiesis before leukemia development shared by Setbp1 overexpression and loss of Runx1. Our transplantation studies of LSK cells transduced by Setbp1 virus suggest that Setbp1 overexpression significantly enhanced the self-renewal capability of HSCs. Setbp1 overexpression may also partially promote the self-renewal of GMPs in vivo as a significantly expanded GMP population was detected after Setbp1 transduction. Similar effects were also elicited by Runx1 loss. Although essential for the onset of definitive hematopoiesis, 29, 30 Runx1 is a negative regulator of HSC self-renewal. 31 Conditional deletion of Runx1 in adult mice caused significant increase in the number of HSCs, although these cells are less competitive than wild-type HSCs in reconstituting irradiated recipient mice because of defective niche interaction. 32, 33 Loss of Runx1 is also associated with partial block of myeloid differentiation leading to expansion of GMPs potentially through its regulation of Sfpi1. 32, 34 These similarities support that Runx1 repression by Setbp1 is a significant contributor to the leukemia-promoting effect of Setbp1.
In contrast to the known function of Setbp1 in activating transcription, our current study suggests that it could also function as a transcriptional repressor to directly repress Runx1 transcription through recruitment of a repressive NuRD complex to Runx1 promoters. A role of the same NuRD complex in repressing tumor suppressor genes in leukemia development has been previously shown by its recruitment by PML-RARα for the repression of RARβ2 in acute promyelocytic leukemia cells. 15 The recruitment of this repressive NuRD complex by Setbp1 could be dependent on promoter context and, therefore, may not occur at Hoxa9 and Hoxa10 because of their activation by Setbp1. It will be interesting to determine in the future whether additional critical repression targets exist for Setbp1 by mapping and comparing the genomewide chromatin-binding profiles of Setbp1 and this NuRD complex in Setbp1 induced leukemia cells.
Consistent with the repression of Runx1 by histone deacetylation induced by the NuRD complex in Setbp1-induced mouse leukemia cells, we found that Runx1 expression can be significantly increased in these cells by HDAC inhibitors, which also efficiently induced their differentiation. HDAC inhibitors including Vorinostat and Romidepsin have been recently approved by the Food and Drug Administration for the treatment of cutaneous T-cell lymphoma, which has validated the usage of HDAC inhibitors for cancer treatment. [35] [36] [37] Studies have also shown that myeloid leukemias induced by AML/ETO, PLZF/RARa or Hoxa9/Meis1 are sensitive to HDAC inhibitors. [25] [26] [27] Our finding that Entinostat treatment significantly extended the survival time of mice with Setbp1-induced leukemias suggests that HDAC inhibitors could be considered for the treatment of acute myeloid leukemias with SETBP1 overexpression in clinic, which were associated with poor prognosis and could represent up to 27% of primary AML patients. 2 Missense mutations of SETBP1 thought to cause stabilization of its protein have also been frequently found in various myeloid malignancies. 3, 4, 7 We found that HDAC inhibitors are equally efficient in inducing differentiation of mouse myeloid progenitors immortalized by one such SETBP1 mutation, further suggesting that HDAC inhibitors could be potentially effective in treating myeloid malignancies with SETBP1 missense mutations. In summary, these studies establish Setbp1 as a potent oncogene for myeloid leukemia development partly through its repression of Runx1 and identify HDAC inhibition as a potentially effective therapeutic strategy for the treatment of human leukemias with SETBP1 activation.
